Search clinical trials for: 9 Peptides from Her-2/neu, CEA, & CTA

Total 66 results

Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer (Breast 37)

Breast Neoplasms

United States
Craig L Slingluff, Jr

Terminated

Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer (Breast 41)

Breast Cancer

United States
University of Washington
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab

Stage IV Breast Cancer | HER2/Neu Positive | HLA-A2 Positive Cells Present | Stage IV Ovarian Cancer

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer

HER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
Mayo Clinic
Marker Therapeutics, Inc.

Completed

Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer

HER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

HER-2 Protein Vaccine in Treating Women With Breast Cancer

Breast Cancer

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer

Colorectal Cancer

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Terminated

Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
University of Washington
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer

HER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer

United States
University of Washington

Completed

Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer

Breast Cancer | Ovarian Cancer | Lung Cancer

United States
University of Washington

Completed

HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer

Breast Cancer | Ovarian Cancer | Lung Cancer

United States
Chinese Society of Hematology
Harbin Institute of Hematology & Oncology

Unknown

Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation Study (MD-CHINA)

Myelodysplastic Syndrome (MDS)
University of Washington
National Cancer Institute (NCI)

Withdrawn

Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer

HER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer

United States
University of Washington
National Cancer Institute (NCI); National Center for Complementary and Integrative...

Completed

Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

Stage IV Breast Cancer | Recurrent Breast Carcinoma | HER2/Neu Positive

United States
University of Washington
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer

HER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer

United States
University of Washington
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IV Breast Cancer

HER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
Military Institute od Medicine National Research...

Completed

Predictive Value of Early Changes of Chromogranin A Levels in Patients With Neuroendocrine Tumours Treated With PRRT

Early Release of Chromogranin A (CgA)
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer

Breast Cancer

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Active, not recruiting

Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery

Pancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | Pancreatic Acinar Cell Carcinoma | Locally Advanced Pancreatic Adenocarcinoma

United States
Novo Nordisk A/S

Recruiting

A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight

Obesity

Canada
New Approaches to Neuroblastoma Therapy Consortium
National Cancer Institute (NCI)

Completed

N99-02: Melphalan and Buthionine Sulfoximine (BSO)

Neuroblastoma

Canada, United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States
National Cancer Institute (NCI)

Completed

Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

Breast Ductal Carcinoma In Situ

United States
University Hospital Muenster
Deutsche Krebshilfe e.V., Bonn (Germany)

Unknown

Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents

Myeloid Leukemia

Germany
Woman's
AstraZeneca

Completed

EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)

Obesity | Polycystic Ovary Syndrome

United States
M.D. Anderson Cancer Center

Active, not recruiting

Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); Eunice Kennedy Shriver... and other collaborators

Completed

Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 (NYM)

Childhood Solid Neoplasm | Metastatic Neoplasm | Adult Solid Neoplasm

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Recruiting

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome | Refractory Mixed Phenotype Acute Leukemia | Refractory Acute Leukemia... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer

Prostate Adenocarcinoma | Male Erectile Disorder | Impotence | Erectile Dysfunction, CTCAE

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | High Risk Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 | Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Acute Myeloid... and other conditions

United States
M.D. Anderson Cancer Center

Active, not recruiting

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia

Previously Treated Myelodysplastic Syndrome | Fanconi Anemia | de Novo Myelodysplastic Syndrome | Acute Myeloid Leukemia in Remission

United States, Brazil
Tanta University
Eman Ibrahim Elberri, Faculty of Pharmacy, Tanta University; Fedaa Abd El-monem... and other collaborators

Recruiting

Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders

Depressive Disorder

Egypt
University of Washington
National Cancer Institute (NCI)

Completed

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

Previously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2 | Myeloid Neoplasm | Chronic Myelomonocytic Leukemia-2 | Blasts 10 Percent or More of Bone Marrow Nucleated... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Recruiting

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Diffuse Large B-Cell Lymphoma | Acute Myeloid Leukemia | Recurrent Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Recurrent Small Lymphocytic Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm | Prolymphocytic Leukemia and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Post-Transplant Lymphoproliferative Disorder | Recurrent Burkitt Lymphoma | Refractory Burkitt Lymphoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

Recurrent Hodgkin Lymphoma | Recurrent Adult Acute Myeloid Leukemia | Recurrent Mantle Cell Lymphoma | Waldenstrom Macroglobulinemia | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Lymphoma | Acute Myeloid Leukemia | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Chronic Phase Chronic Myelogenous Leukemia | Recurrent Small Lymphocytic Lymphoma | Chronic Myelogenous Leukemia | Refractory Chronic Lymphocytic Leukemia and other conditions

United States
Fred Hutchinson Cancer Center

Completed

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant

Myelodysplastic Syndrome (MDS) | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Biphenotypic Leukemia | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission | Blasts Under 5 Percent of Bone Marrow...

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | T-Cell Prolymphocytic Leukemia | B-Cell Prolymphocytic Leukemia

United States, Italy
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Suspended

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | Recurrent Acute Lymphoblastic... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Diffuse Large B-Cell Lymphoma | Acute Myeloid Leukemia | Refractory Hodgkin Lymphoma | Waldenstrom Macroglobulinemia | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Prolymphocytic Leukemia | Refractory... and other conditions

United States, Germany, Denmark
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; Canadian Cancer Trials Group; Southwest Oncology... and other collaborators

Completed

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

HER2 Positive Breast Carcinoma | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States, Canada, Peru, South Africa
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Myeloproliferative Neoplasm | Paroxysmal Nocturnal Hemoglobinuria | de Novo Myelodysplastic Syndrome | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Refractory Anemia | Refractory Anemia With... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia With PML-RARA

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

Immunodeficiency Syndrome | Non-Cancer Diagnosis

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Hodgkin Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Childhood Acute Lymphoblastic Leukemia | Plasma Cell Myeloma | Recurrent Diffuse Large B-Cell Lymphoma | Prolymphocytic Leukemia | Refractory Chronic... and other conditions

United States, Denmark

Search clinical trials for: 9 Peptides from Her-2/neu, CEA, & CTA

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations